Pharmacology of botulinum toxins;Pharmakologie der botulinumtoxine

Nervenheilkunde

Volumn 25, Issue 7, 2006, Pages 521-526

  Dressler, Dirk ^a   Benecke, R ^a  

^a UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

Adverse effects; Antibodies; Botulinum toxin; Mode of action; Pharmacology; Therapy

Indexed keywords

BOTULINUM TOXIN; BOTULINUM TOXIN A; BOTULINUM TOXIN B; NEUROTOXIN;

AUTONOMIC NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; HUMAN; MUSCLE SPINDLE; NEUROMUSCULAR BLOCKING; NEUROMUSCULAR TRANSMISSION; NEUROTRANSMISSION; REVIEW; UNSPECIFIED SIDE EFFECT;

EID: 33846600919     PISSN: 07221541     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1626747     Document Type: Review

References (50)

1. Benecke R, Jost WH, Kanovsky P, Ruzicka E, Comes G, Grafe S. A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia. Neurology 2005; 64: 1949-51.
2. Binz T, Blasi J, Yamasaki S, Baumeister A, Link E, Sudhof TC, Jahn R, Niemann H. Proteolysis of SNAP-25 by types E and A botulinal neurotoxins. J Biol Chem 1994; 269: 1617-20.
3. Brin MF, Dressler D, Aoki R. Pharmacology of botulinum toxin therapy. In: Jankovic J, Comella C, Brin MF (eds). Dystonia: Etiology, Clinical Features, and Treatment. Philadelphia: Lippincott Williams & Wilkins 2004; 93-112.
4. Cui M, Li Z, You S, Khanijou S, Aoki R. Mechanisms of the antinociceptive effect of subcutaneous Botox: inhibition of peripheral and central nociceptive processing. Arch Pharmacol 2002; 365: R17.
5. de Paiva A, Meunier FA, Molgo J, Aoki KR, Dolly JO. Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Proc Natl Acad Sci USA 1999; 96: 3200-5.
6. Dressler D, Bigalke H. Botulinum toxin type B de novo therapy of cervical dystonia: frequency of antibody-induced therapy failure. J Neurol 2005; 252: 904-7.
7. Dressler D, Benecke R. Autonomic side effects of botulinum toxin type B treatment of cervical dystonia and hyperhidrosis. Eur Neurol 2003; 49: 34-8.
8. Dressler D, Adib Saberi F, Benecke R. Botulinum toxin type B for treatment of axillar hyperhidrosis. J Neurol 249; 2002: 1729-32.
9. Dressler D. Dysport produces intrinsically more swallowing problems than Botox: Unexpected results from a conversion factor study in cervical dystonia. J Neurol Neurosurg Psychiatry 2002; 73: 604.
10. Dressler D, Dirnberger G. Botulinum toxin therapy: Risk factors for therapy failure. Mov Disord 2000; 15 (suppl 2): 51.
11. Dressler D, Rothwell JC, Bigalke H. The sternocleidomastoid test: an in-vivo assay to investigate botulinum toxin antibody formation in man. J Neurol 2000; 247: 630-2.
12. Dressler D, Rothwell JC. Electromyographic quantification of the paralysing effect of botulinum toxin. Eur Neurol 2000; 43: 13-6.
13. Dressler D. Botulinum Toxin Therapy. Stuttgart, New York: Thieme Verlag 2000.
14. Dressler D, Eckert J, Kukowski B, Meyer BU. Somatosensorisch Evozierte Potentiale bei Schreibkrampf: Normalisierung pathologischer Befunde unter Botulinumtoxin Therapie. Z EEG EMG 1993; 24: 191.
15. Dressler D, Benecke R, Conrad B. Botulinum-Toxin in der Therapie kraniozervikaler Dystonien. Nervenarzt 1989; 60: 386-94.
16. Duchen LW. An electron microscopic study of the changes induced by botulinum toxin in the motor end-plates of slow and fast skeletal muscle fibres of the mouse. J Neurol Sci. 1971; 14: 47-60.
17. Duchen LW. Changes in the electron microscopic structure of slow and fast skeletal muscle fibres of the mouse after the local injection of botulinum toxin. J Neurol Sci 1971; 14: 61-74.
18. Erbguth F, Claus D, Engelhardt A, Dressler D. Systemic effect of local botulinum toxin injections unmasks subclinical Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiat 1993; 56: 1235-6.
19. Filippi GM, Errico P, Santarelli R, Bagolini B, Manni E. Botulinum A toxin effects on rat jaw muscle spindles. Acta Otolaryngol 1993; 113: 400-4.
20. Foran P, Lawrence GW, Shone CC, Foster KA, Dolly JO. Botulinum neurotoxin C1 cleaves both syntaxin and SNAP-25 in intact and permeabilized chromaffin cells: correlation with its blockade of catecholamine release. Biochemistry 1996; 35: 2630-6.
21. Girlanda P, Vita G, Nicolosi C, Milone S, Messina. Botulinum toxin therapy: distant effects on neuromuscular transmission and autonomic nervous system. J Neurol Neurosurg Psychiatry 1992; 55: 844-5.
22. Ishikawa H, Mitsui Y, Yoshitomi T, Mashimo K, Aoki S, Mukuno K, Shimizu K. Presynaptic effects of botulinum toxin type A on the neuronally evoked response of albino and pigmented rabbit iris sphincter and dilator muscles. Jpn J Ophthalmol 2000; 44: 106-9.
23. Jankovic J, Vuong KD, Ahsan J. Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia. Neurology 2003; 60: 1186-8.
24. Kaji R, Kohara N, Katayama M, Kubori T, Mezaki T, Shibasaki H, Kimura J. Muscle afferent block by intramuscular injection of lidocaine for the treatment of writer's cramp. Muscle Nerve 1995; 18: 234-5.
25. Kaji R, Rothwell JC, Katayama M, Ikeda T, Kubori T, Kohara N, Mezaki T, Shibasaki H, Kimura J. Tonic vibration reflex and muscle afferent block in writer's cramp. Ann Neuro 1995; 138: 155-62.
26. Kerner J. Das Fettgift und die Fettsäure und ihre Wirkungen auf den tierischen Organismus. Ein Beitrag zur Untersuchung des in verdorbenen Würsten giftig wirkenden Stoffes. Stuttgart, Tübingen: Cotta-Verlag 1822.
27. Kerner J. Neue Beobachtungen über die in Württemberg so häufig vorfallenden tödlichen Vergiftungen durch den Genuss geräucherter Würste. Tübingen: G F Osiander 1820.
28. Kerner J. Vergiftung durch verdorbene Würste. Tübinger Blätter f Naturwissensch u Arzneykunde 1817; 3: 1-25.
29. Lange DJ, Brin MF, Warner CL, Fahn S, Lovelace RE. Distant effects of local injection of botulinum toxin. Muscle Nerve 1987; 10: 552-5.
30. McMahon H, Foran P, Dolly J. Tetanus toxin and botulinum toxins type A and B inhibit glutamate, gamma-aminobutyric acid, aspartate, and met-enkephalin release from synaptosomes: clues to the locus of action. J Biol Chem 1992; 267: 21338-43.
31. Morris J, Jobling P, Gibbins I. Differential inhibition by botulinum neurotoxin A of cotransmitters released from autonomic vasodilator neurons. Am J Physiol Heart Circ Physiol 2001; 281: 2124-32.
32. Olney RK, Aminoff MJ, Gelb DJ, Lowenstein DH. Neuromuscular effects distant from the site of botulinum neurotoxin injection. Neurology 1988; 38: 1780-3.
33. Pellizzari R, Rossetto O, Schiavo G, Montecucco C. Tetanus and botulinum neurotoxins: mechanism of action and therapeutic uses. Philos Trans R Soc Lond B Biol Sci 1999; 354: 259-68.
34. th Annual Meeting of the Interagency Botulism Research Coordinating Committee (IBRCC), Nov. 2003, Atlanta, USA.
35. Probst TE, Heise H, Heise P, Benecke R, Dressler D. Rare immunologic side effects of botulinum toxin therapy: brachial plexus neuropathy and dermatomyositis. Mov Disord 2002; 17 (suppl 5): S49.
36. Purkiss J, Welch M, Doward S, Foster K. Capsaicin-stimulated release of substance P from cultured dorsal root ganglion neurons: involvement of two distinct mechanisms. Biochem Pharmacol 2000; 59: 1403-6.
37. Rosales RL, Arimura K, Takenaga S, Osame M. Extrafusal and intrafusal muscle effects in experimental botulinum toxin-A injection. Muscle Nerve 1996; 19: 488-96.
38. Sanders DB, Massey EW, Buckley EG. Botulinum toxin for blepharospasm: single-fibre EMG studies. Neurology 1986; 36: 545-7.
39. Schantz EJ. Historical Perspective. In: Jankovic J, Hallett M: Therapy with Botulinum Toxin. New York, Basel, Hong Kong: Marcel Dekker, Inc. 1994; pp XXIII-XXVI.
40. Schiavo G, Santucci A, Dasgupta BR, Mehta PP, Jontes J, Benfenati F, Wilson MC, Montecucco C. Botulinum neurotoxins serotypes A and E cleave SNAP-25 at distinct COOH-terminal peptide bonds. FEBS Lett. 1993; 335: 99-103.
41. Schiavo G, Benfenati F, Poulain B, Rossetto O, Polverino de Laureto P, DasGupta BR, Montecucco C. Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin. Nature 1992; 359: 832-5.
42. Scott AB. Foreword. In: Jankovic J, Hallett M: Therapy with Botulinum Toxin. New York, Basel, Hong Kong: Marcel Dekker, Inc. 1994; pp VII-IX.
43. Scott AB. Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. J Pediatr Ophthalmol Strabismus 1980; 17: 21-5.
44. Scott AB, Rosenbaum A, Collins CC. Pharmacologic weakening of extraocular muscles. Invest Ophthalmol 1973; 12: 924-7.
45. Setler P. The biochemistry of botulinum toxin type B. Neurology 2000; 55(Suppl 5): S22-S28.
46. Shone CC, Melling J. Inhibition of calcium-dependent release of noradrenaline from PC12 cells by botulinum type-A neurotoxin. Long-term effects of the neurotoxin on intact cells. Eur J Biochem 1992; 207: 1009-16.
47. Takamizawa K, Iwamori M, Kozaki S, Sakaguchi G, Tanaka R, Takayama H, Nagai Y. TLC immunostaining characterization of Clostridium botulinum type A neurotoxin binding to gangliosides and free fatty acids. FEBS Lett 1986; 201: 229-32.
48. Welch MJ, Purkiss JR, Foster KA. Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins. Toxicon 2000; 38: 245-58.
49. Wiegand H, Erdmann G, Wellhoner HH. 125I-labelled botulinum A neurotoxin: pharmacokinetics in cats after intramuscular injection. Naunyn Schmiedebergs Arch Pharmacol 1976; 292: 161-5.
50. Yamasaki S et al. Cleavage of members of the synaptobrevin/VAMP family by types D and F botulinal neurotoxins and tetanus toxin. J Biol Chem 1994; 269: 12764-72.